Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpNew England Journal of Medicine
• journal#1
Aaron S Kelly, Pernille Auerbach, Margarita Barrientos-Perez, Inge Gies, Paula M Hale, Claude Marcus, Lucy D Mastrandrea, Nandana Prabhu, Silva Arslanian
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3...
March 31, 2020: New England Journal of Medicine
#2
Jonathan Gruber, Benjamin D Sommers
No abstract text is available yet for this article.
March 31, 2020: New England Journal of Medicine
#3
Muthiah Vaduganathan, Orly Vardeny, Thomas Michel, John J V McMurray, Marc A Pfeffer, Scott D Solomon
No abstract text is available yet for this article.
March 30, 2020: New England Journal of Medicine
#4
Caroline G Dunn, Erica Kenney, Sheila E Fleischhacker, Sara N Bleich
No abstract text is available yet for this article.
March 30, 2020: New England Journal of Medicine
#5
Pavan K Bhatraju, Bijan J Ghassemieh, Michelle Nichols, Richard Kim, Keith R Jerome, Arun K Nalla, Alexander L Greninger, Sudhakar Pipavath, Mark M Wurfel, Laura Evans, Patricia A Kritek, T Eoin West, Andrew Luks, Anthony Gerbino, Chris R Dale, Jason D Goldman, Shane O'Mahony, Carmen Mikacenic
BACKGROUND: Community transmission of coronavirus 2019 (Covid-19) was detected in the state of Washington in February 2020. METHODS: We identified patients from nine Seattle-area hospitals who were admitted to the intensive care unit (ICU) with confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Clinical data were obtained through review of medical records. The data reported here are those available through March 23, 2020. Each patient had at least 14 days of follow-up...
March 30, 2020: New England Journal of Medicine
#6
Nicole Lurie, Melanie Saville, Richard Hatchett, Jane Halton
No abstract text is available yet for this article.
March 30, 2020: New England Journal of Medicine
#7
Sripal Bangalore, David J Maron, Sean M O'Brien, Jerome L Fleg, Evgeny I Kretov, Carlo Briguori, Upendra Kaul, Harmony R Reynolds, Tomasz Mazurek, Mandeep S Sidhu, Jeffrey S Berger, Roy O Mathew, Olga Bockeria, Samuel Broderick, Radoslaw Pracon, Charles A Herzog, Zhen Huang, Gregg W Stone, William E Boden, Jonathan D Newman, Ziad A Ali, Daniel B Mark, John A Spertus, Karen P Alexander, Bernard R Chaitman, Glenn M Chertow, Judith S Hochman
BACKGROUND: Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease. METHODS: We randomly assigned 777 patients with advanced kidney disease and moderate or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of coronary angiography and revascularization (if appropriate) added to medical therapy or an initial conservative strategy consisting of medical therapy alone and angiography reserved for those in whom medical therapy had failed...
March 30, 2020: New England Journal of Medicine
#8
David J Maron, Judith S Hochman, Harmony R Reynolds, Sripal Bangalore, Sean M O'Brien, William E Boden, Bernard R Chaitman, Roxy Senior, Jose López-Sendón, Karen P Alexander, Renato D Lopes, Leslee J Shaw, Jeffrey S Berger, Jonathan D Newman, Mandeep S Sidhu, Shaun G Goodman, Witold Ruzyllo, Gilbert Gosselin, Aldo P Maggioni, Harvey D White, Balram Bhargava, James K Min, G B John Mancini, Daniel S Berman, Michael H Picard, Raymond Y Kwong, Ziad A Ali, Daniel B Mark, John A Spertus, Mangalath N Krishnan, Ahmed Elghamaz, Nagaraja Moorthy, Whady A Hueb, Marcin Demkow, Kreton Mavromatis, Olga Bockeria, Jesus Peteiro, Todd D Miller, Hanna Szwed, Rolf Doerr, Matyas Keltai, Joseph B Selvanayagam, P Gabriel Steg, Claes Held, Shun Kohsaka, Stavroula Mavromichalis, Ruth Kirby, Neal O Jeffries, Frank E Harrell, Frank W Rockhold, Samuel Broderick, T Bruce Ferguson, David O Williams, Robert A Harrington, Gregg W Stone, Yves Rosenberg
BACKGROUND: Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. METHODS: We randomly assigned 5179 patients with moderate or severe ischemia to an initial invasive strategy (angiography and revascularization when feasible) and medical therapy or to an initial conservative strategy of medical therapy alone and angiography if medical therapy failed...
March 30, 2020: New England Journal of Medicine
#9
John A Spertus, Philip G Jones, David J Maron, Daniel B Mark, Sean M O'Brien, Jerome L Fleg, Harmony R Reynolds, Gregg W Stone, Mandeep S Sidhu, Bernard R Chaitman, Glenn M Chertow, Judith S Hochman, Sripal Bangalore
BACKGROUND: In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) as compared with guideline-based medical therapy alone (conservative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease (an estimated glomerular filtration rate of <30 ml per minute per 1...
March 30, 2020: New England Journal of Medicine
#10
John A Spertus, Philip G Jones, David J Maron, Sean M O'Brien, Harmony R Reynolds, Yves Rosenberg, Gregg W Stone, Frank E Harrell, William E Boden, William S Weintraub, Khaula Baloch, Kreton Mavromatis, Ariel Diaz, Gilbert Gosselin, Jonathan D Newman, Stavroula Mavromichalis, Karen P Alexander, David J Cohen, Sripal Bangalore, Judith S Hochman, Daniel B Mark
BACKGROUND: In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients. METHODS: We assessed angina-related symptoms, function, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1...
March 30, 2020: New England Journal of Medicine
#11
EDITORIAL
Elliott M Antman, Eugene Braunwald
No abstract text is available yet for this article.
March 30, 2020: New England Journal of Medicine
#12
Vincent J Nijenhuis, Jorn Brouwer, Ronak Delewi, Renicus S Hermanides, Wouter Holvoet, Christophe L F Dubois, Peter Frambach, Bernard De Bruyne, Gert K van Houwelingen, Jan A S Van Der Heyden, Petr Toušek, Frank van der Kley, Ian Buysschaert, Carl E Schotborgh, Bert Ferdinande, Pim van der Harst, John Roosen, Joyce Peper, Frederick W F Thielen, Leo Veenstra, Dean R P P Chan Pin Yin, Martin J Swaans, Benno J W M Rensing, Arnoud W J van 't Hof, Leo Timmers, Johannes C Kelder, Pieter R Stella, Jan Baan, Jurriën M Ten Berg
BACKGROUND: The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied. METHODS: We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months. The two primary outcomes were all bleeding and non-procedure-related bleeding over a period of 12 months...
March 29, 2020: New England Journal of Medicine
#13
EDITORIAL
Agnes Y Y Lee
No abstract text is available yet for this article.
March 29, 2020: New England Journal of Medicine
#14
EDITORIAL
Frederick Feit
No abstract text is available yet for this article.
March 29, 2020: New England Journal of Medicine
#15
C Marc Samama, Silvy Laporte, Nadia Rosencher, Philippe Girard, Juan Llau, Patrick Mouret, William Fisher, Javier Martínez-Martín, Daniel Duverger, Béatrice Deygas, Emilie Presles, Michel Cucherat, Patrick Mismetti
BACKGROUND: Nonmajor orthopedic surgery of the lower limbs that results in transient reduced mobility places patients at risk for venous thromboembolism. Rivaroxaban may be noninferior to enoxaparin with regard to the prevention of major venous thromboembolism in these patients. METHODS: In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin...
March 29, 2020: New England Journal of Medicine
#16
Giancarlo Agnelli, Cecilia Becattini, Guy Meyer, Andres Muñoz, Menno V Huisman, Jean M Connors, Alexander Cohen, Rupert Bauersachs, Benjamin Brenner, Adam Torbicki, Maria R Sueiro, Catherine Lambert, Gualberto Gussoni, Mauro Campanini, Andrea Fontanella, Giorgio Vescovo, Melina Verso
BACKGROUND: Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use. METHODS: This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial with blinded central outcome adjudication. We randomly assigned consecutive patients with cancer who had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg twice daily for the first 7 days, followed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily for the first month, followed by 150 IU per kilogram once daily)...
March 29, 2020: New England Journal of Medicine
#17
Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Mark R Nehler, Manesh R Patel, Fabrizio Fanelli, Warren H Capell, Lihong Diao, Nicole Jaeger, Connie N Hess, Akos F Pap, John M Kittelson, Ivan Gudz, Lajos Mátyás, Dainis K Krievins, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, William R Hiatt
BACKGROUND: Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain. METHODS: In a double-blind trial, patients with peripheral artery disease who had undergone revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) plus aspirin or placebo plus aspirin. The primary efficacy outcome was a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes...
March 28, 2020: New England Journal of Medicine
#18
Paul W Armstrong, Burkert Pieske, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Javed Butler, Carolyn S P Lam, Piotr Ponikowski, Adriaan A Voors, Gang Jia, Steven E McNulty, Mahesh J Patel, Lothar Roessig, Joerg Koglin, Christopher M O'Connor
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose, 10 mg once daily) or placebo, in addition to guideline-based medical therapy...
March 28, 2020: New England Journal of Medicine
#19
Temet M McMichael, Dustin W Currie, Shauna Clark, Sargis Pogosjans, Meagan Kay, Noah G Schwartz, James Lewis, Atar Baer, Vance Kawakami, Margaret D Lukoff, Jessica Ferro, Claire Brostrom-Smith, Thomas D Rea, Michael R Sayre, Francis X Riedo, Denny Russell, Brian Hiatt, Patricia Montgomery, Agam K Rao, Eric J Chow, Farrell Tobolowsky, Michael J Hughes, Ana C Bardossy, Lisa P Oakley, Jesica R Jacobs, Nimalie D Stone, Sujan C Reddy, John A Jernigan, Margaret A Honein, Thomas A Clark, Jeffrey S Duchin
BACKGROUND: Long-term care facilities are high-risk settings for severe outcomes from outbreaks of Covid-19, owing to both the advanced age and frequent chronic underlying health conditions of the residents and the movement of health care personnel among facilities in a region. METHODS: After identification on February 28, 2020, of a confirmed case of Covid-19 in a skilled nursing facility in King County, Washington, Public Health-Seattle and King County, aided by the Centers for Disease Control and Prevention, launched a case investigation, contact tracing, quarantine of exposed persons, isolation of confirmed and suspected cases, and on-site enhancement of infection prevention and control...
March 27, 2020: New England Journal of Medicine
#20
Kathleen R Page, Maya Venkataramani, Chris Beyrer, Sarah Polk
No abstract text is available yet for this article.
March 27, 2020: New England Journal of Medicine
Fetching more papers... 
